The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study
Vedolizumab as induction and maintenance therapy for Crohn's disease.
The efficacy of vedolizumab, an α4β7 integrin antibody, in Crohn's disease is unknown. ⋯ Vedolizumab-treated patients with active Crohn's disease were more likely than patients receiving placebo to have a remission, but not a CDAI-100 response, at week 6; patients with a response to induction therapy who continued to receive vedolizumab (rather than switching to placebo) were more likely to be in remission at week 52. Adverse events were more common with vedolizumab. (Funded by Millennium Pharmaceuticals; GEMINI 2 ClinicalTrials.gov number, NCT00783692.).